Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Nektar Therapeutics's share was trading at $35.23 as of January 29th. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. NKTR has strengthened its immunology platform with new data that expands the potential of its lead asset, Rezpegaldesleukin (Rezpeg), and widens its market reach. Rezpeg, already backed by two FDA Fast Track designations and strong Phase 2b REZOLVE-AD results in atopic dermatitis, has now delivered late-breaking findings in patients with comorbid asthma—an opportunity affecting roughly a quarter of eczema patients. In the main Phase 2b trial, Rezpeg produced 53–61% EASI improvement across dosing cohorts versus 31% for placebo, with a clean safety profile and only eight drug-related severe or serious events, all resolved. The newly released asthma analysis shows that over 50% of Rezpeg-treated patients
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.MarketBeat
- An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics (NASDAQ:NKTR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/27/26 - Form 8-K
- 1/22/26 - Form 4
- NKTR's page on the SEC website